Evidence map›Paper›PMID 42426368›Full record

ArticleEuropean journal of clinical pharmacology2026

Serum concentrations and pharmacokinetics of linezolid in critically ill patients dialyzed by ADVanced Organ Support compared to conventional continuous renal replacement therapy.

Julian Triebelhorn, Johanna Erber, Heike Schneider, Jochen Schneider, Laura Wagner, Yizhu Li, Eva Ortner, Roland M Schmid, Ulrich Mayr, Tobias Lahmer and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Julian TriebelhornTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Johanna ErberTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Heike SchneiderTUM School of Medicine and Health- Clinical Department of Clinical Chemistry and Laboratory Medicine, TUM University Hospital, Munich, Germany.
Jochen SchneiderTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Laura WagnerTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Yizhu LiTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Eva OrtnerTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Roland M SchmidTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Ulrich MayrTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Tobias LahmerTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany.
Miriam DibosTUM School of Medicine and Health- Clinical Department of Internal Medicine II, TUM University Hospital, Ismaninger Str. 22, Munich, 81675, Germany. miriam.dibos@mri.tum.de.ORCID https://orcid.org/0000-0001-7778-3283

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDosing of antibiotics proves to be both crucial and especially challenging in critically ill patients due to extracorporeal therapies. In this exploratory study, we compared the influence of the albumin based ADVanced Organ Support (ADVOS) system to conventional continuous venovenous hemodialysis (CVVHD) on linezolid serum concentrations.

methodsA total of 14 critically ill patients (8 ADVOS, 6 CVVHD) receiving linezolid 600 mg twice daily were analyzed, comprising 22 measurement cycles. Machine clearance was calculated by pre- and post-filter concentrations; total and patient clearance were estimated by area under the curve (AUC) calculations. Linezolid pharmacokinetics were evaluated by C

resultsMachine clearance was significantly higher in ADVOS than in CVVHD (median 3.4 vs. 1.6 L/h, p < 0.001), accounting for a higher share of total clearance (38.1% vs. 18.2%). Total clearance (9.3 vs. 10.4 L/h) and patient clearance (6.7 vs. 8.4 L/h) did not differ significantly, nor did AUC24 (250.9 vs. 221.2 mg·h/L) or Cmin (4.6 vs. 4.0 mg/L). A substantial proportion of subtherapeutic serum concentrations was observed in both groups (45.5% by AUC24 and 31.8% by Cmin).

conclusionThis in-vivo study provides real-life data of linezolid levels in ICU-patients treated with conventional CVVHD and ADVOS. The high occurrence of subtherapeutic serum concentrations and a significant difference in dialysis capacities depending on dialysis type indicate the necessity of a tailored therapeutic drug monitoring approach in this vulnerable population.

Indexed as

Anti-Bacterial AgentsContinuous Renal Replacement TherapyLinezolidRenal DialysisAgedArea Under CurveCritical IllnessFemaleHumansMaleMiddle AgedAnti-Bacterial AgentsLinezolidADVOSClearanceDialysisICULinezolid

Identifiers

PMID42426368
PMCPMC13350108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.